Pfizer Licenses OTC Nexium Rights From AstraZeneca
This article was originally published in The Pink Sheet Daily
Pfizer will make an upfront payment of $250 million for global rights to market a potential 20 mg OTC version of proton pump inhibitor Nexium, currently available only by prescription. Filing of Rx-to-OTC switch application expected in first half of 2013.
You may also be interested in...
Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.
"We're particularly concerned about the health care area right now because obviously that's driving everything now," says Tennessee AG Herbert Slatery III. He and CRN CEO Steve Mister spoke with HBW Insight about regulation of the consumer health marketplace with FDA suspending inspections of facilities operated by businesses manufacturing and marketing products subject to its oversight.
It’s unlikely any industry stakeholder or FDA official expected a bill providing emergency economic relief to consumers, industries and health care services and facilities in response to a pandemic, including extensive support opportunities for small businesses, would be the vehicle that delivers on both of the industry’s congressional wishes. The supplement industry also looks for help in CARES Act.